Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Genetic Technologies Ltd (GENE)
NASDAQ:GENE
Holding GENE?
Track your performance easily
GENE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.67 - $3.72
Previous Close$0.77
Volume22.67K
Average Volume (3M)21.52K
Market Cap
$6.21M
Enterprise Value$6.10M
Total Cash (Recent Filing)AU$1.04M
Total Debt (Recent Filing)AU$875.19K
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Feb 26, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.83
Shares Outstanding4,847,242
10 Day Avg. Volume0
30 Day Avg. Volume21,523
Standard Deviation0.23
R-Squared0.06
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)2.01
Price to Sales (P/S)0.56
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Genetic Technologies News
PremiumCompany Announcements
Genetic Technologies Faces NASDAQ Compliance Challenge
PremiumCompany Announcements
Genetic Technologies Embraces Corporate Governance Standards
PremiumCompany Announcements
Genetic Technologies Reinforces Governance StandardsPremiumCompany Announcements
Genetic Technologies Expands Global Access to geneType™
Ownership Overview
―
Insiders
0.01% Mutual Funds
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GENE FAQ
What was Genetic Technologies Ltd’s price range in the past 12 months?
Genetic Technologies Ltd lowest stock price was $0.67 and its highest was $3.72 in the past 12 months.
What is Genetic Technologies Ltd’s market cap?
Currently, no data Available
When is Genetic Technologies Ltd’s upcoming earnings report date?
Genetic Technologies Ltd’s upcoming earnings report date is Feb 26, 2025 which is in 105 days.
How were Genetic Technologies Ltd’s earnings last quarter?
Genetic Technologies Ltd released its earnings results on Aug 29, 2024. The company reported -$0.799 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.799.
Is Genetic Technologies Ltd overvalued?
According to Wall Street analysts Genetic Technologies Ltd’s price is currently Overvalued.
Does Genetic Technologies Ltd pay dividends?
Genetic Technologies Ltd does not currently pay dividends.
What is Genetic Technologies Ltd’s EPS estimate?
Genetic Technologies Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genetic Technologies Ltd have?
Genetic Technologies Ltd has 4,847,241 shares outstanding.
What happened to Genetic Technologies Ltd’s price movement after its last earnings report?
Genetic Technologies Ltd reported an EPS of -$0.799 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Genetic Technologies Ltd?
Currently, no hedge funds are holding shares in GENE
---
Genetic Technologies Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-78.12%
12-Months-Change
Fundamentals
Return on Equity
-181.97%
Trailing 12-Months
Asset Growth
-58.22%
Trailing 12-Months
Company Description
Genetic Technologies Ltd
Genetic Technologies Ltd. engages in the provision of molecular risk assessment for cancer. It operates through the USA and Australia geographical segments. Its product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The company was founded on January 5, 1987 and is headquartered in Fitzroy, Australia.
---
Technical Analysis
---